|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Roder DM: The epidemiology of gastric
cancer. Gastric Cancer. 5(Suppl 1): 5–11. 2002. View Article : Google Scholar
|
|
3
|
Paoletti X, Oba K, Burzykowski T, et al:
Benefit of adjuvant chemotherapy for resectable gastric cancer: a
meta-analysis. JAMA. 303:1729–1737. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu JH, Song LB, Zhang X, et al: Bmi-1
expression predicts prognosis for patients with gastric carcinoma.
J Surg Oncol. 97:267–272. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gou HF, Chen XC, Zhu J, et al: Expressions
of COX-2 and VEGF-C in gastric cancer: correlations with
lymphangiogenesis and prognostic implications. J Exp Clin Cancer
Res. 30:142011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Aoki M, Ishigami S, Uenosono Y, et al:
Expression of BMP-7 in human gastric cancer and its clinical
significance. Br J Cancer. 104:714–718. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou F, Li N, Jiang W, et al: Prognosis
significance of HER-2/neu overexpression/amplification in Chinese
patients with curatively resected gastric cancer after the ToGA
clinical trial. World J Surg Oncol. 10:2742012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li W, Yu CP, Xia JT, et al: Sphingosine
kinase 1 is associated with gastric cancer progression and poor
survival of patients. Clin Cancer Res. 15:1393–1399. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kladney RD, Bulla GA, Guo L, et al: GP73,
a novel Golgi-localized protein upregulated by viral infection.
Gene. 249:53–65. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mao Y, Yang H, Xu H, et al: Golgi protein
73 (GOLPH2) is a valuable serum marker for hepatocellular
carcinoma. Gut. 59:1687–1693. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kristiansen G, Fritzsche FR, Wassermann K,
et al: GOLPH2 protein expression as a novel tissue biomarker for
prostate cancer: implications for tissue-based diagnostics. Br J
Cancer. 99:939–948. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fritzsche FR, Riener MO, Dietel M, Moch H,
Jung K and Kristiansen G: GOLPH2 expression in renal cell cancer.
BMC Urol. 8:152008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fritzsche FR, Kristiansen G, Riener MO,
Dietel M and Oelrich B: GOLPH2 expression may serve as diagnostic
marker in seminomas. BMC Urol. 10:42010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang F, Gu Y, Li X, Wang W, He J and Peng
T: Up-regulated Golgi phosphoprotein 2 (GOLPH2) expression in lung
adenocarcinoma tissue. Clin Biochem. 43:983–991. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Marrero JA, Romano PR, Nikolaeva O, et al:
GP73, a resident Golgi glycoprotein, is a novel serum marker for
hepatocellular carcinoma. J Hepatol. 43:1007–1012. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Riener MO, Stenner F, Liewen H, et al:
Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its
value as a serum marker in hepatocellular carcinomas. Hepatology.
49:1602–1609. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kladney RD, Cui X, Bulla GA, Brunt EM and
Fimmel CJ: Expression of GP73, a resident Golgi membrane protein,
in viral and nonviral liver disease. Hepatology. 35:1431–1440.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu JS, Wu DW, Liang S and Miao XY: GP73, a
resident Golgi glycoprotein, is sensibility and specificity for
hepatocellular carcinoma of diagnosis in a hepatitis B-endemic
Asian population. Med Oncol. 27:339–345. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang M, Long RE, Comunale MA, et al: Novel
fucosylated biomarkers for the early detection of hepatocellular
carcinoma. Cancer Epidemiol Biomarkers Prev. 18:1914–1921. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu X, Wan X, Li Z, Lin C, Zhan Y and Lu
X: Golgi protein 73(GP73), a useful serum marker in liver diseases.
Clin Chem Lab Med. 49:1311–1316. 2011.PubMed/NCBI
|
|
21
|
Iftikhar R, Kladney RD, Havlioglu N, et
al: Disease- and cell-specific expression of GP73 in human liver
disease. Am J Gastroenterol. 99:1087–1095. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hann HW, Wang M, Hafner J, et al: Analysis
of GP73 in patients with HCC as a function of anti-cancer
treatment. Cancer Biomark. 7:269–273. 2010.PubMed/NCBI
|
|
23
|
Ozkan H, Erdal H, Tutkak H, et al:
Diagnostic and prognostic validity of Golgi protein 73 in
hepatocellular carcinoma. Digestion. 83:83–88. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Laxman B, Morris DS, Yu J, et al: A
first-generation multiplex biomarker analysis of urine for the
early detection of prostate cancer. Cancer Res. 68:645–649. 2008.
View Article : Google Scholar : PubMed/NCBI
|
